CELESTIA: Cost-Effectiveness Analysis of Empagliflozin Versus Sitagliptin in Patients with Type 2 Diabetes in Greece

References

• Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of type 2 diabetes – global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10(1):107–111. doi:10.2991/jegh.k.191028.001
   PubMed Web of Science ®Google Scholar
• Saeedi P, Petersohn I, Salpea P, et al; IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843. doi:10.1016/j.diabres.2019.107843
   PubMed Web of Science ®Google Scholar
• Liatis S, Dafoulas GE, Kani C, et al. The prevalence and treatment patterns of diabetes in the Greek population based on real-world data from the nation-wide prescription database. Diabetes Res Clin Pract. 2016;118:162–167. doi:10.1016/j.diabres.2016.06.018
   PubMed Web of Science ®Google Scholar
• Migdalis I, Rombopoulos G, Hatzikou M, Manes C, Kypraios N, Tentolouris N. The cost of managing type 2 diabetes mellitus in Greece: a retrospective analysis of 10-year patient level data “The HERCULES study”. Int J Endocrinol. 2015;2015:520759. doi:10.1155/2015/520759
   PubMed Web of Science ®Google Scholar
• Patel A, MacMahon S, Chalmers J, et al; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572. doi:10.1056/NEJMoa0802987
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589. doi:10.1056/NEJMoa0806470
   PubMed Web of Science ®Google Scholar
• Ismail-Beigi F, Craven T, Banerji MA, et al; ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376(9739):419–430. doi:10.1016/S0140-6736(10)60576-4
   PubMed Web of Science ®Google Scholar
• Stettler C, Allemann S, Jüni P, et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J. 2006;152(1):27–38. doi:10.1016/j.ahj.2005.09.015
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. NICE guideline [NG28]: type 2 diabetes in adults: management; 2021.
   Google Scholar
• Kearney PM, Blackwell L, Collins R, et al; Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117–125. doi:10.1016/S0140-6736(08)60104-X
   PubMed Web of Science ®Google Scholar
• Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–591. doi:10.1056/NEJMoa0706245
   PubMed Web of Science ®Google Scholar
• Griffin SJ, Borch-Johnsen K, Davies MJ, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet. 2011;378(9786):156–167. doi:10.1016/S0140-6736(11)60698-3
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703–713.
   PubMed Web of Science ®Google Scholar
• Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43(2):487–493. doi:10.2337/dci19-0066
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. The CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20(Suppl 1):S5–S26. doi:10.1185/030079904X1980
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Med Res Opin. 2004;20(Suppl 1):S27–S40. PMID: 15324514. doi:10.1185/030079904X2006
   PubMed Web of Science ®Google Scholar
• McEwan P, Foos V, Palmer JL, Lamotte M, Lloyd A, Grant D. Validation of the IMS CORE diabetes model. Value Health. 2014;17(6):714–724. doi:10.1016/j.jval.2014.07.007
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Consensus Panel. Guidelines for computer modeling of diabetes and its complications. Diabetes Care. 2004;27(9):2262–2265. doi:10.2337/diacare.27.9.2262
   PubMed Web of Science ®Google Scholar
• Tzanetakos C, Melidonis A, Verras C, Kourlaba G, Maniadakis N. Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled type 2 diabetes on oral antidiabetic drugs in Greece. BMC Health Serv Res. 2014;14:419. doi:10.1186/1472-6963-14-419
   PubMed Web of Science ®Google Scholar
• Gourzoulidis G, Tzanetakos C, Ioannidis I, et al. Cost-effectiveness of empagliflozin for the treatment of patients with type 2 diabetes mellitus at increased cardiovascular risk in Greece. Clin Drug Investig. 2018;38(5):417–426. doi:10.1007/s40261-018-0620-x
   PubMed Web of Science ®Google Scholar
• Häring HU, Merker L, Seewaldt-Becker E, et al; EMPA-REG MET Trial Investigators. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014;37(6):1650–1659. doi:10.2337/dc13-2105
   PubMed Web of Science ®Google Scholar
• Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™). Cardiovasc Diabetol. 2014;13:102. doi:10.1186/1475-2840-13-102
   PubMed Web of Science ®Google Scholar
• Balijepalli C, Shirali R, Kandaswamy P, et al. Cardiovascular safety of empagliflozin versus dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes: systematic literature review and indirect comparisons. Diabetes Ther. 2018;9(4):1491–1500. doi:10.1007/s13300-018-0456-7
   PubMed Web of Science ®Google Scholar
• Ramos M, Foos V, Ustyugova A, Hau N, Gandhi P, Lamotte M. Cost-effectiveness analysis of empagliflozin in comparison to sitagliptin and saxagliptin based on cardiovascular outcome trials in patients with type 2 diabetes and established cardiovascular disease. Diabetes Ther. 2019;10(6):2153–2167. doi:10.1007/s13300-019-00701-3
   PubMed Web of Science ®Google Scholar
• Ramos M, Ustyugova A, Hau N, Lamotte M. Cost-effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in type II diabetes. J Comp Eff Res. 2020;9(11):781–794. doi:10.2217/cer-2020-0071
   PubMed Web of Science ®Google Scholar
• Ramos M, Men P, Wang X, Ustyugova A, Lamotte M. Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China. Cost Eff Resour Alloc. 2021;19(1):46. doi:10.1186/s12962-021-00299-z
   PubMed Web of Science ®Google Scholar
• Wanner C, Inzucchi SE, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–334. doi:10.1056/NEJMoa1515920
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel MA, Armstrong PW, et al; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–242. doi:10.1056/NEJMoa1501352
   PubMed Web of Science ®Google Scholar
• Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom prospective diabetes study: UKPDS 82. Diabetologia. 2013;56(9):1925–1933. doi:10.1007/s00125-013-2940-y
   PubMed Web of Science ®Google Scholar
• Bain SC, Hansen BB, Malkin SJP, et al. Oral semaglutide versus empagliflozin, sitagliptin and liraglutide in the UK: long-term cost-effectiveness analyses based on the PIONEER clinical trial programme. Diabetes Ther. 2020;11(1):259–277. doi:10.1007/s13300-019-00736-6
   PubMed Web of Science ®Google Scholar
• Malkin SJP, Hunt B, Huisman EL, Grand TS, Chubb B. The long-term cost-effectiveness of oral semaglutide in the Netherlands based on the PIONEER 2, 3 and 4 randomized controlled trials. Diabetes Res Clin Pract. 2021;175:108759. doi:10.1016/j.diabres.2021.108759
   PubMed Web of Science ®Google Scholar
• Fonseca V, Gill J, Zhou R, Leahy J. An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycemia. Diabetes Obes Metab. 2011;13(9):814–822. doi:10.1111/j.1463-1326.2011.01412.x
   PubMed Web of Science ®Google Scholar
• Riddle MC, Bolli GB, Ziemen M, et al; EDITION 1 Study Investigators. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care. 2014;37(10):2755–2762. doi:10.2337/dc14-0991
   PubMed Web of Science ®Google Scholar
• Liatis S, Iraklianou S, Kazakos K, et al; AGREEMENT Investigators. A Greek registry of current type 2 diabetes management, aiming to determine core clinical approaches, patterns and strategies. BMC Endocr Disord. 2019;19(1):39. doi:10.1186/s12902-019-0364-5
   PubMedGoogle Scholar
• Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ. 2005;14(3):217–230. PMID: 15386666. doi:10.1002/hec.910
   PubMed Web of Science ®Google Scholar
• Greek Ministry of Health. Drug price bulletin; 2021. Available from: https://www.moh.gov.gr/articles/times-farmakwn/deltia-timwn/9022-laquo-epikairopoihsh-deltioy-timwn-farmakwn-anthrwpinhs-xrhshs-me-enswmatwsh-dioikhtikwn-metabolwn-raquo. Accessed May 29, 2022.
   Google Scholar
• Tzanetakos C, Tentolouris N, Kourlaba G, Maniadakis N. Cost-effectiveness of dapagliflozin as add-on to metformin for the treatment of type 2 diabetes mellitus in Greece. Clin Drug Investig. 2016;36(8):649–659. doi:10.1007/s40261-016-0410-2
   PubMed Web of Science ®Google Scholar
• Hellenic Statistical Authority. Inflation rates. Available from: https://www.statistics.gr/en/home/. Accessed December 09, 2021.
   Google Scholar
• Tzanetakos C, Stefanou G, Gourzoulidis G. PNS61 does a standard willingness-to-pay threshold exist in Greece? Value Health. 2019;22:S772–S773.
   PubMed Web of Science ®Google Scholar
• Tentolouris A, Eleftheriadou I, Athanasakis K, et al. Prevalence of diabetes mellitus as well as cardiac and other main comorbidities in a representative sample of the adult Greek population in comparison with the general population. Hellenic J Cardiol. 2020;61(1):15–22. doi:10.1016/j.hjc.2018.04.008
   PubMed Web of Science ®Google Scholar
• Reifsnider O, Kansal A, Pimple P, Aponte-Ribero V, Brand S, Shetty S. Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States. Diabetes Obes Metab. 2021;23(3):791–799. doi:10.1111/dom.14268
   PubMed Web of Science ®Google Scholar
• Patorno E, Pawar A, Wexler DJ, et al. Effectiveness and safety of empagliflozin in routine care patients: results from the EMPagliflozin comparative effectIveness and SafEty (EMPRISE) study. Diabetes Obes Metab. 2022;24(3):442–454. doi:10.1111/dom.14593
   PubMed Web of Science ®Google Scholar